Singapore markets closed

AbbVie Inc. (ABBV)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
150.00-0.57 (-0.38%)
At close: 04:03PM EDT
150.00 0.00 (0.00%)
After hours: 07:50PM EDT

AbbVie Inc.

1 North Waukegan Road
North Chicago, IL 60064-6400
United States
847 932 7900
https://www.abbvie.com

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full-time employees50,000

Key executives

NameTitlePayExercisedYear born
Mr. Richard A. GonzalezChairman & CEO7.42M19.91M1954
Dr. Michael E. Severino M.D.Vice Chairman & Pres4.29MN/A1966
Mr. Robert A. MichaelVice Chairman of Fin. & Commercial Operations and CFO3.82MN/A1970
Ms. Laura J. SchumacherVice Chairman of External Affairs, Chief Legal Officer & Corp. Sec.4.18M13.28M1963
Mr. Jeffrey Ryan StewartExec. VP & Chief Commercial Officer3.25MN/A1969
Dr. Azita Saleki-Gerhardt Ph.D.Exec. VP of OperationsN/AN/A1963
Dr. Thomas J. HudsonSr. VP of R&D and Chief Scientific OfficerN/AN/A1962
Ms. Elizabeth SheaVP of Investor RelationsN/AN/AN/A
Mr. Timothy J. RichmondExec. VP & Chief HR OfficerN/AN/A1966
Mr. Henry O. GosebruchExec. VP & Chief Strategy OfficerN/AN/A1973
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Corporate governance

AbbVie Inc.’s ISS governance QualityScore as of 1 May 2022 is 8. The pillar scores are Audit: 9; Board: 5; Shareholder rights: 9; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.